thiothixene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2639 | 3313-26-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 24, 1967 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AF04 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Thioxanthene derivatives |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| CHEBI has role | CHEBI:149553 | anticoronaviral drug |
| FDA EPC | N0000180182 | Typical Antipsychotic |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Senile dementia | contraindication | 15662003 | |
| Agranulocytosis | contraindication | 17182001 | DOID:12987 |
| Shock | contraindication | 27942005 | |
| Parkinsonism | contraindication | 32798002 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Stupor | contraindication | 89458003 | |
| Tardive dyskinesia | contraindication | 102449007 | |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Alcohol withdrawal syndrome | contraindication | 191480000 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Coma | contraindication | 371632003 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Drug Induced CNS Depression | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.72 | Basic |
| pKa2 | 4.65 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.35 | PDSP | CHEMBL | |||
| Alpha-2A adrenergic receptor | GPCR | Ki | 7.10 | PDSP | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.41 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.39 | PDSP | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 7.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.87 | PDSP | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.68 | PDSP | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 7.82 | PDSP | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 7.94 | PDSP | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.30 | PDSP | |||||
| D(3) dopamine receptor | GPCR | Ki | 9.41 | PDSP | |||||
| D(1B) dopamine receptor | GPCR | Ki | 6.58 | PDSP | |||||
| Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 8.40 | IUPHAR | ||||
| Histamine H2 receptor | GPCR | Ki | 6.39 | PDSP | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.59 | PDSP | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.68 | PDSP | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.40 | PDSP | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.81 | PDSP | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.32 | PDSP | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.82 | PDSP | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 6.18 | PDSP | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.28 | PDSP | |||||
| D(4) dopamine receptor | GPCR | Ki | 6.69 | PDSP | |||||
| 5-hydroxytryptamine receptor 3A | Ion channel | Ki | 5.73 | PDSP | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 7.46 | PDSP | |||||
| D(1A) dopamine receptor | GPCR | Ki | 7.29 | PDSP | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.44 | PDSP |
External reference:
| ID | Source |
|---|---|
| 4019947 | VUID |
| N0000148032 | NUI |
| D00374 | KEGG_DRUG |
| 4018509 | VANDF |
| 4019947 | VANDF |
| C0039955 | UMLSCUI |
| CHEBI:9571 | CHEBI |
| CHEMBL1201 | ChEMBL_ID |
| D013888 | MESH_DESCRIPTOR_UI |
| DB01623 | DRUGBANK_ID |
| 212 | IUPHAR_LIGAND_ID |
| 2114 | INN_ID |
| 22189-31-7 | SECONDARY_CAS_RN |
| 7318FJ13YJ | UNII |
| 941651 | PUBCHEM_CID |
| 10510 | RXNORM |
| 2137 | MMSL |
| 5574 | MMSL |
| 5575 | MMSL |
| d00391 | MMSL |
| 001529 | NDDF |
| 001530 | NDDF |
| 25538002 | SNOMEDCT_US |
| 372804006 | SNOMEDCT_US |
| 62529008 | SNOMEDCT_US |
| CHEMBL3989824 | ChEMBL_ID |
| CHEMBL1200902 | ChEMBL_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1001 | CAPSULE | 1 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1001 | CAPSULE | 1 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2002 | CAPSULE | 2 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2002 | CAPSULE | 2 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3005 | CAPSULE | 5 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3005 | CAPSULE | 5 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5010 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5010 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-161 | CAPSULE | 5 mg | ORAL | ANDA | 18 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-587 | CAPSULE | 2 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-587 | CAPSULE | 2 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-588 | CAPSULE | 5 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-588 | CAPSULE | 5 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-589 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-589 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-275 | CAPSULE | 1 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-275 | CAPSULE | 1 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-276 | CAPSULE | 2 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-276 | CAPSULE | 2 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-277 | CAPSULE | 5 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-277 | CAPSULE | 5 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-278 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-278 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0817 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-1129 | CAPSULE | 2 mg | ORAL | ANDA | 16 sections |
| thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1673 | CAPSULE | 1 mg | ORAL | ANDA | 17 sections |
| thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1674 | CAPSULE | 2 mg | ORAL | ANDA | 17 sections |
| thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1675 | CAPSULE | 5 mg | ORAL | ANDA | 17 sections |
| thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1676 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2486 | CAPSULE | 5 mg | ORAL | ANDA | 16 sections |